You are here

Our science / Clinical Trials / Find a Trial / NCT01856569

Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy

Back to Search Print Save as PDF Bookmark Trial

NCT01856569

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Unita Operativa Semplice di Reumatologia
Catania, CT, 95100 Italy
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months
observation AS patients with axial involvement

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

patients in other AS studies involved

NCT01856569
Pfizer
Completed
Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ankylosing Spondylitis
Etanercept Withdrawal And Retreatment Study In Subjects With Non- Radiographic Axial Spondyloarthritis (Chronic Lower Back Pain)
NCT02509026
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
NCT00273858
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
NCT01786668
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
NCT00421980
All Genders
18+
Years
Gent,
Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Assial - Anti Tnf Treatment In Ankylosing Spondylitis: An Observational Cohort Study In Italy
Observe in real life adherence therapy and time to switch in ankylosing spondylitis patients with predominant assial involvement with 4 anti-TNF.
retrospective and prospective 150
Observational
Observational Model: Cohort
Time Perspective: Other
Not Provided
Not Provided
Probability Sample
ankylosing spondylitis
Ankylosing Spondylitis
Other: no intervention
in real life of drug,dosage,frequency and duration
Other Name: adherence of therapy,switching,combo therapy
observational
Intervention: Other: no intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
152
November 2015
October 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months observation AS patients with axial involvement

Exclusion Criteria:

patients in other AS studies involved
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01856569
B1801362
B1801362
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now